Alberto Cordero1, Enrique Galve2, Vicente Bertomeu-Martínez3, Héctor Bueno4, Lorenzo Fácila5, Eduardo Alegría6, Ángel Cequier7, Emilio Ruiz8, José Ramón González-Juanatey9. 1. Departamento de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain. Electronic address: acorderofort@gmail.com. 2. Departamento de Cardiología, Hospital Vall d'Hebron, Barcelona, Spain. 3. Departamento de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain. 4. Departamento de Cardiología, Hospital 12 de Octubre, Madrid, Spain. 5. Departamento de Cardiología, Hospital General de Valencia, Valencia, Spain. 6. Departamento de Cardiología, Policlínica Gipuzkoa, San Sebastián, Guipúzcoa, Spain. 7. Departamento de Cardiología, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. 8. Departamento Médico, Laboratorios Ferrer, Barcelona, Spain. 9. Departamento de Cardiología, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.
Abstract
INTRODUCTION AND OBJECTIVES: Chronic ischemic heart disease is the most prevalent of all cardiovascular diseases. Patients are at high risk of complications. In recent decades, changes may have occurred in the clinical characteristics of the disease, its treatment and control of risk factors. METHODS: A direct comparison of 2 national registries of patients with chronic ischemic heart disease carried out in 2006 (n=1583) and 2014 (n=1110). RESULTS: We observed statistically significant differences between the 2 registries, with a higher percentage of men and smokers in the 2014 registry, but a lower prevalence of diabetes mellitus and hypertension. Heart failure and stroke were more prevalent in the 2006 registry. Patients in the 2014 registry had better results for lipid profile, blood glucose, creatinine, and glomerular filtration rate. We observed higher use of recommended drugs for secondary prevention and an increased percentage of patients receiving optimal medical therapy, from 32.5% to 49.5% (P<.01). Use of high-intensity statin doses also increased from 10.5% to 42.8% (P<.01). We found better control of some risk factors (improved dyslipidemia, heart rate, and blood glucose in patients with diabetes) but worse blood pressure control. CONCLUSIONS: The clinical profile of patients with chronic ischemic heart disease is similar in the 2 registries. There has been an improvement in patients' medical therapy and dyslipidemia control, blood glucose, and heart rate, but there is still much room for improvement in the control of other cardiovascular risk factors.
INTRODUCTION AND OBJECTIVES: Chronic ischemic heart disease is the most prevalent of all cardiovascular diseases. Patients are at high risk of complications. In recent decades, changes may have occurred in the clinical characteristics of the disease, its treatment and control of risk factors. METHODS: A direct comparison of 2 national registries of patients with chronic ischemic heart disease carried out in 2006 (n=1583) and 2014 (n=1110). RESULTS: We observed statistically significant differences between the 2 registries, with a higher percentage of men and smokers in the 2014 registry, but a lower prevalence of diabetes mellitus and hypertension. Heart failure and stroke were more prevalent in the 2006 registry. Patients in the 2014 registry had better results for lipid profile, blood glucose, creatinine, and glomerular filtration rate. We observed higher use of recommended drugs for secondary prevention and an increased percentage of patients receiving optimal medical therapy, from 32.5% to 49.5% (P<.01). Use of high-intensity statin doses also increased from 10.5% to 42.8% (P<.01). We found better control of some risk factors (improved dyslipidemia, heart rate, and blood glucose in patients with diabetes) but worse blood pressure control. CONCLUSIONS: The clinical profile of patients with chronic ischemic heart disease is similar in the 2 registries. There has been an improvement in patients' medical therapy and dyslipidemia control, blood glucose, and heart rate, but there is still much room for improvement in the control of other cardiovascular risk factors.
Authors: Alberto Cordero; Moisés Rodríguez-Mañero; Lorenzo Fácila; M Rosa Fernández-Olmo; Manuel J Gómez-Martínez; Alfonso Valle; Jose Mª Castellano; Miriam Martín Toro; José Seijas-Amigo; Alvaro Vicedo; José R González-Juanatey Journal: J Diabetes Metab Disord Date: 2020-06-01